Impax releases generic version of dutasteride capsules, 0.5 mg

Download PDF Copy

Editorial Checklist

Reviewed

Impax Laboratories, Inc.Nov 24 2015

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. The Company immediately initiated commercialization activities through its generic division. This is the 13^th generic product launched in 2015 by Impax's generic division.

According to IMS Health (NSP), U.S. brand and generic sales of dutasteride capsules, 0.5 mg were approximately $457 million for the 12 months ending in September 2015.

Source:

Impax Laboratories, Inc.

Posted in: Pharmaceutical News

Tags: Drug Delivery, Dutasteride, Food, Healthcare, Manufacturing, Nervous System, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Research reveals inaccuracies in common gene therapy measurement technique

Research reveals inaccuracies in common gene therapy measurement technique

U.S. launches national plan to tackle Parkinson's disease and related disorders

U.S. launches national plan to tackle Parkinson's disease and related disorders

New drug cocktail enhances CAR-T cells for cancer treatment

New drug cocktail enhances CAR-T cells for cancer treatment

COVID-19 infection linked to increased cases of ME/CFS

COVID-19 infection linked to increased cases of ME/CFS

Understanding how the skin's neurons process social touch signals

Understanding how the skin's neurons process social touch signals

Anhedonia: The hidden psychological toll of deep endometriosis

Anhedonia: The hidden psychological toll of deep endometriosis

How stress fuels allergic skin inflammation

How stress fuels allergic skin inflammation

The crucial role of 'chaperones' in maintaining neuronal function

The crucial role of 'chaperones' in maintaining neuronal function

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study reveals route of entry for Semliki Forest virus into the brain